
KCP backs YorkTest MBO
Key Capital Partners (KCP) has backed the management buyout of YorkTest Laboratories from Ingemino, backed by CBPE Capital.
CBPE will sell its complete stake in the food intolerance testing business, which was originally a bolt-on for another of its portfolio companies, Ingemino. KCP will acquire a majority stake in the business with an investment of £8.6m, backing the incumbent management. The deal was prompted by the management and no debt was involved.
James Hall, a partner at KCP who led the investment team alongside Seb Wilkinson, will join the board of YorkTest. Meanwhile, the deal is the fourth for KCP's latest fund, which closed on £70m and makes buyout investments of £3-15m.
CBPE's Ingemino purchased a majority stake in YorkTest in 2011, with fresh capital provided by CBPE to finance the deal.
Company
YorkTest offers support to customers in identifying food intolerance and guiding them through dietary changes. The company has a York-based laboratory, with most of its sales made directly through its website. It trades under the brand names YorkTest and Lorisian.
In 2016, the company generated £3.7m in sales, with profit before tax of £855,378. Its largest market is the UK.
People
YorkTest – Rachel Jansen (managing director).
Key Capital Partners – James Hall (partner).
Advisers
Equity – Addleshaw Goddard (legal); BDO (financial due diligence); CIL (commercial due diligence); PwC (tax).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater